You are here
A/Professor Daryl Efron
A/Prof Efron is a senior research fellow at the Murdoch Children's Research Institute and has worked as a paediatrician at the Royal Children's Hospital for over 30 years. He is also an Associate Professor of Paediatrics at the University of Melbourne.
Daryl has a 25-year record in child neurodisability research and is a recognised clinical and academic leader in developmental paediatrics in Australia. He sees children with a wide range of health concerns, from babies through to teenagers, and enjoys working with families to develop creative solutions to difficult problems.
One of the current research interests of Daryl and his team are the therapeutic uses of cannabinoids to treat severe behavioural problems in children and adolescents with intellectual disabilities and autism.
Daryl's influential roles in organisations such as the Australian Paediatric Research Network, the Neurodevelopmental Behavioural Paediatric Society of Australasia, and the Australian ADHD Professionals Association have proven effective mechanisms for the dissemination of research findings into practice. He has demonstrated evidence-based clinical translation and innovation, including establishing three multidisciplinary clinics for children with neurodevelopmental disorders: ADHD, epilepsy-associated neurodisability, and Tourette disorder.
A/Prof Efron has attracted $6.3M in nationally competitive grants, held a number of roles with the Royal Australasian College of Physician, and has had over 50 papers published in the last 5 years.
- Associate Professor of Paediatrics, University of Melbourne
- Consultant paediatrician, Royal Children's Hospital
Improved management of behaviours of concern in children and adolescents with intellectual disability and/or autism spectrum disorder.
This project will develop a new model of care to improve support for families of children with severe behavioural problems associated with Intellectual Disability and/or ASD. This project will be improvement science based. We will recruit patients/families and work through a series of iterative Plan, Do, Study, Act cycles. This project will result in much improved care for these extremely vulnerable patients. Outcomes will include more timely access to care, increased consumer participation in care, and reduced crisis presentations to the emergency department.
Parent, paediatrician and child psychiatrist attitudes to and understanding of medicinal cannabis for treating emotional, behavioural and/or mental health symptoms
The potential benefits and side effects of medical cannabis (MC) for the management of developmental, behavioural and mental health symptoms in children and adolescents has not been well studied. However MC is now able to be prescribed. This situation is creating uncertainty for both prescribers and families. The aim of this survey is to gauge the current understanding of, and attitudes to, medical cannabis use for development, behavioural and mental health conditions among parents, paediatricians and child and adolescent psychiatrists.
Understanding the impact of COVID-19 on the functioning and wellbeing of children and adolescents with neurodevelopmental disorders and their families
This study aims understand the impact of COVID-19 on the functioning and wellbeing of Australian children and adolescents with Neurodevelopmental Disorders (NDDs) and their families. NDDs include Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), intellectual disability, cerebral palsy and Tourette syndrome. Parents will be asked to complete a baseline survey, followed for brief surveys each 2 months for a 6 month period. Surveys will ask about areas including the child's emotional health and behaviour, learning in lockdown, access to services, family functioning and the mental health of parents.
- Efron D, Mulraney M, Sciberras E et al. Patterns of long-term ADHD medication use in Australian children. Arch Dis Child, 2019, 10.1136/archdischild-2019-317997.
- Efron D, Cranswick NE, Gulenc A, et al. Medication Prescribed by Paediatricians: Psychotropics predominate. J Paediatr Child Health. 2017;53:957-962.
- Efron D, Gulenc A, Sciberras E, et al. Prevalence and Predictors of Medication use in Children with ADHD: Evidence from a Community-based Longitudinal Study. J Child Adolesc Psychopharmacology
- Efron D, Payne J, Gulenc A, Chan E et al. Assessment and management of tic disorders and Tourette syndrome by Australian paediatricians: Tourette Syndrome management. Journal of Paediatrics and Child Health 2019, 56(1).
- Efron D, Freeman J, Cranswick N et al. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability. Br J Clin Pharmacol (in press)